Clinical Trials on T-Cell/Histiocyte-Rich Large B-Cell Lymphoma in New Zealand

Total 974 results

National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Plasmablastic Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell... and other conditions

United States
Malaghan Institute of Medical Research
Wellington Zhaotai Therapies Limited (WZTL)

Recruiting

ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) (ENABLE)

Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Lymphomas Non-Hodgkin's B-Cell | Transformed Follicular Lymphoma (TFL) | Primary Mediastinal B-cell Lymphoma (PMBCL)

New Zealand
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC

Completed

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Peripheral T-Cell Lymphoma

United States
miRagen Therapeutics, Inc.

Completed

Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL

Chronic Lymphocytic Leukemia (CLL) | Cutaneous T-cell Lymphoma (CTCL) | Mycosis Fungoides (MF) | Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype | Adult T-Cell Leukemia/Lymphoma (ATLL)

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of MLN8237 in Participants With Advanced Hematological Malignancies

Multiple Myeloma | Waldenstrom's Macroglobulinemia | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B-cell Lymphoma | B-Cell Chronic Lymphocytic Leukemia | Enteropathy Associated T-cell Lymphoma | B-cell Follicular Lymphoma | B-cell Marginal Zone Lymphoma | B-cell Mantle... and other conditions

United States
Canadian Cancer Trials Group
Celgene

Completed

Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma | Peripheral T-Cell Lymphoma

Canada
National Cancer Institute (NCI)

Recruiting

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

T-cell Large Granular Lymphocyte Leukemia | T-cell Lymphomas | T-cell Prolymphocytic Leukemia | NK-Cell Lymphomas

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma

Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma | Burkitt's Lymphoma | T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma | Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component

United States
National Cancer Institute (NCI)

Recruiting

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Lymphoplasmacytic Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Grade 3b Follicular... and other conditions

United States
Seagen Inc.

Recruiting

A Safety Study of SGN-35T in Adults With Advanced Cancers

Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Hodgkin Disease | Lymphoma, T-Cell, Cutaneous | Lymphoma, T-Cell, Peripheral | Lymphoma, Large-Cell, Anaplastic

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Anaplastic Large Cell Lymphoma, ALK-Positive | Adult T-Cell Leukemia/Lymphoma | Angioimmunoblastic T-Cell Lymphoma | Hepatosplenic T-Cell Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Enteropathy-Associated T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Anaplastic... and other conditions

United States, Canada
Memorial Sloan Kettering Cancer Center

Recruiting

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

Lymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell Lymphoma

United States
Schrödinger, Inc.

Recruiting

Study of SGR-1505 in Mature B-Cell Neoplasms

Follicular Lymphoma | Splenic Marginal Zone Lymphoma | Burkitt Lymphoma | Plasmablastic Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Non Hodgkin Lymphoma | Primary Effusion Lymphoma | DLBCL | High-grade B-cell Lymphoma | Primary Mediastinal... and other conditions

United States, Moldova, Republic of
Morphotek
National Cancer Institute (NCI); Children's Oncology Group

Completed

MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Unspecified Childhood Solid Tumor, Protocol Specific | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Terminated

Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Refractory Anaplastic Large Cell Lymphoma | Refractory Transformed Non-Hodgkin Lymphoma | Recurrent...

United States
University of Rochester

Terminated

A Phase II Study of Doxycycline in Relapsed NHL

Lymphoma, Follicular | Waldenstrom Macroglobulinemia | T-Cell Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma | Adult Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma Recurrent | Marginal Zone B-Cell Lymphoma | Malignant Lymphoma - Lymphoplasmacytic

United States
National Cancer Institute (NCI)

Active, not recruiting

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Burkitt Lymphoma | Primary Mediastinal Large B-cell Lymphoma | Gray Zone Lymphoma | Diffuse Large B-Cell Lymphoma (DLBCL) | Anaplastic Large-Cell Lymphoma

United States
VelosBio Inc., a subsidiary of Merck & Co., Inc...

Completed

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

Follicular Lymphoma | Acute Myeloid Leukemia | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Acute Lymphoid Leukemia | Richter Transformation Lymphoma | Lymphoplasmacytoid Lymphoma | T-cell Non-Hodgkin...

United States
Synthekine

Recruiting

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | NHL | CLL/SLL | Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Registry for People With T-cell Lymphoma

Mycosis Fungoides | Sezary Syndrome | Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | T-cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Primary Cutaneous Anaplastic Large... and other conditions

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Amgen

Active, not recruiting

Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive | Stage I Diffuse Large B-Cell Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma and other conditions

United States
Novartis Pharmaceuticals

Completed

CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)

Acute Lymphoblastic Leukemia (ALL) | Diffuse Large B-Cell Lymphoma (DLBCL)

United States
University of Nebraska
National Cancer Institute (NCI)

Completed

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

Anaplastic Large Cell Lymphoma, ALK-Positive | Hepatosplenic T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Anaplastic Large Cell Lymphoma, ALK-Negative | Stage II Angioimmunoblastic T-cell Lymphoma | Stage II Enteropathy-Associated T-Cell Lymphoma | Stage III Angioimmunoblastic... and other conditions

United States
Kymera Therapeutics, Inc.

Recruiting

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

Solid Tumors | T-cell Prolymphocytic Leukemia (T-PLL) | Non Hodgkin Lymphoma (NHL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-Cell Lymphoma (CTCL) | Large Granular Lymphocytic Leukemia (LGL-L)

United States
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Withdrawn

Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Merck Sharp & Dohme LLC

Recruiting

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)

Relapsed Diffuse Large B-cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

Australia, Spain, United States, France, Hungary, New Zealand, Poland, Serbia, Canada, Romania
MEI Pharma, Inc.

Terminated

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone B Cell Lymphoma | High Grade Non-Hodgkin's Lymphoma

United States, Switzerland
Memorial Sloan Kettering Cancer Center
Sanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaborators

Active, not recruiting

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)

United States
Bristol-Myers Squibb

Withdrawn

MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

Lymphoma, Large-Cell

United States, France
Icahn School of Medicine at Mount Sinai
Bristol-Myers Squibb

Completed

Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United States
Amgen

Completed

AMG 319 Lymphoid Malignancy FIH

Lymphoma | Leukemia | Cancer | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Hematologic Malignancies | Diffuse Large Cell Lymphoma | Oncology | Tumors | T Cell Lymphoma | Oncology Patients | Hematology | Low Grade Lymphoma

United States
Hackensack Meridian Health
Janssen Scientific Affairs, LLC; Genentech, Inc.

Active, not recruiting

A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Unspecified Childhood Solid Tumor, Protocol Specific | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Childhood Chronic Myelogenous Leukemia | Cutaneous B-cell Non-Hodgkin Lymphoma | Hepatosplenic T-cell Lymphoma | Intraocular Lymphoma | Recurrent Childhood Acute Lymphoblastic... and other conditions

United States, Canada
Seagen Inc.

Completed

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

Large Cell Lymphoma

United States
Acrotech Biopharma Inc.

Completed

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Mycosis Fungoides | Sezary Syndrome | Cutaneous T-cell Lymphoma | Primary Cutaneous Anaplastic Large Cell Lymphoma

United States, Italy
Weill Medical College of Cornell University
Epizyme, Inc.; American Society of Clinical Oncology; Applebaum Foundation

Recruiting

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-Cell Lymphoma

United States
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL)

United States
Hoffmann-La Roche

Terminated

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Lymphoma, Large B-Cell, Diffuse | Follicular Lymphoma

United States, Australia, Germany, Korea, Republic of, New Zealand
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC; Novartis Pharmaceuticals

Completed

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

Lymphoma | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma

United States
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC; Xynomic Pharmaceuticals, Inc.

Active, not recruiting

Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma

United States
Weill Medical College of Cornell University

Completed

Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)

Diffuse Large B-cell Lymphoma

United States
Pharmacyclics LLC.
Celgene Corporation

Completed

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma Refractory | Diffuse Large B Cell Lymphoma Relapsed

United States
Weill Medical College of Cornell University
Celgene

Completed

Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma

United States
Weill Medical College of Cornell University
Bristol-Myers Squibb

Terminated

A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas

Lymphoma | Diffuse Large B-Cell Lymphoma | Hodgkin Lymphoma | Burkitt Lymphoma | Anaplastic Large Cell Lymphoma

United States, Canada
Incyte Corporation

Completed

A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United States
Autolus Limited

Completed

CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER)

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell Lymphoma

United States, United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Follicular Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Peripheral T-cell Lymphoma | Lymphoid Malignancies | Chronic Lymphoid Leukemia

United States, Canada

Clinical Trials on T-Cell/Histiocyte-Rich Large B-Cell Lymphoma in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations